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Abstract
Background: Responsiveness, or sensitivity to clinical change, is an important consideration in
selection of a health-related quality of life (HRQL) measure for trials or clinical applications. Many
approaches can be used to assess responsiveness, which may affect the interpretation of study
results. We compared the relative responsiveness of generic and heart failure specific HRQL
instruments, as measured both by common psychometric indices and by external clinical criteria.
Methods: We analyzed data collected at baseline and 6-weeks in 298 subjects with heart failure
on the following HRQL measures: EQ-5D (US, UK, and VAS Scoring), Kansas City Cardiomyopathy
Questionnaire (KCCQ) (Clinical and Overall Summary Score), and RAND12 (Physical and Mental
Component Summaries). Three external indicators of clinical change were used to classify subjects
as improved, deteriorated, or unchanged: 6-minute walk test, New York Heart Association
(NYHA) class, and physician global rating of change. Four responsiveness statistics (T-test, effect
size, Guyatt's responsiveness statistic, and standardized response mean) were used to evaluate the
responsiveness of the select measures. The m e d i a n  r a n k  o f  e a c h  H R Q L  m e a s u r e  a c r o s s
responsiveness indices and clinical criteria was then determined.
Results: Average age of subjects was 60 years, 75 percent were male, and had moderate to severe
heart failure symptoms. Overall, the KCCQ Summary Scores had the highest relative ranking,
irrespective of the responsiveness index or external criterion used. Importantly, we observed that
the relative ranking of responsiveness of the generic measures (i.e. EQ-5D, RAND12) was
influenced by both the responsive indices and external criterion used.
Conclusion: The disease specific KCCQ was the most responsive HRQL measure assessing
change over a 6-week period, although generic measures provide information for which the KCCQ
is not suitable. The responsiveness of generic HRQL measures may be affected by the index used,
as well as the external criterion to classify patients who have clinically change or remained stable.
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Background
In chronic medical conditions, small changes in clinical
status must be readily identifiable to monitor patients'
progress and to modify treatment strategies, if necessary
[1]. In heart failure, for example, numerous clinical indi-
cators are employed to monitor patients' health status
over time, including physician assessments (e.g., New
York Heart Association (NYHA) classification system),
exercise capacity (e.g., six-minute walk test), fluctuations
in body weight, and biomarkers [2]. Often, however,
changes in patients' own perceptions of their health status
may not be readily apparent to the clinician or may not be
manifested in a manner that easily lends itself to these
assessments. As a result, self-reported health-related qual-
ity of life (HRQL) measures are increasingly being used to
provide complementary and additional insight into the
health status of a patient or patients [3-6].
HRQL measures have been commonly used in the clinical
trial setting in the evaluation of new treatment strategies,
and more recently are even used as the primary outcome
assessment for clinical trials [7,8]. When used as the pri-
mary outcome, identification and quantification of subtle
changes in a patients' health status is critical since the suc-
cess or failure of the trial depends entirely on the HRQL
measure. It is therefore essential that the HRQL measure
be sensitive to small, but important, changes to determine
if the treatment under study is effective or potentially
harmful to the patient.
Several disease and generic measures of HRQL have been
used in both clinical practice and in clinical trials of
patients with heart failure. To accurately capture these
changes in health status over time, the HRQL measure
must have evidence of longitudinal validity or 'respon-
siveness' [9]. Responsiveness refers to the ability of a
HRQL measure to capture true underlying change in the
patients' health status over time [9]. Two approaches are
commonly used to assess the responsiveness of HRQL
measures. The first method, the distributional approach,
imparts meaning to the HRQL score by evaluating the
changes in the HRQL scores and their associated variabil-
ity (i.e., standard deviation). Often distributional based
methods establish the responsiveness of a HRQL measure
by the degree of 'statistical significance' associated with
the change score. Importantly, however, the interpretabil-
ity of the data is completely dependent on the variability
of the data and a 'statistically significant' change may not
necessarily constitute a clinically important change (or
vice-versa), thereby limiting their ability to evaluate
responsiveness. The second method, anchored-based
approaches, compares the changes in HRQL scores to
other clinically meaningfully markers or anchors. Anchor-
based approaches are often easier to interpret for clinical
audiences than the distributional-based approaches.
Importantly, however, the external anchor chosen must
itself be a valid measure of clinical change.
Several factors may therefore influence the responsiveness
of a HRQL measure, including, but not limited to, the
content of the measure (i.e., disease-specific versus
generic), the validity of the measure, the error associated
with the HRQL scores, the indices used to determine the
responsiveness (e.g., T-statistics, effect sizes, etc) and the
external criterion or 'gold standard' used to identify sub-
jects as changed or not changed. When considering evi-
dence of responsiveness, it is important to consider the
extent to which these factors affect reported estimates of
responsiveness [9].
To provide empirical evidence to support this issue, and to
assist in the selection and interpretation of health status
measures for heart failure, we analyzed longitudinal
HRQL data in patients with heart failure to evaluate the
relative responsiveness of selected disease-specific and
generic HRQL measures. We explicitly compared their rel-
ative performance as measured by common responsive-




Patients with heart failure were recruited through the Car-
diovascular Outcomes Research Consortium across 14
medical center outpatient departments in the United
States and Canada [2]. All subjects were 30 years of age or
older with documented left ventricular systolic dysfunc-
tion (left ventricular ejection fraction < 0.40). There were
no exclusions, particularly with respect to the upper age
limit. The subjects included in the study were typical of
heart failure subjects in an outpatient setting. This was a
cohort study aimed at evaluating the random changes
observed in heart failure patients in the outpatient setting.
No specific intervention was studied in these patients dur-
ing the follow-up period.
HRQL and clinical measures
Patients completed several HRQL questionnaires at base-
line, including the RAND12, EQ-5D, and the Kansas City
Cardiomyopathy Questionnaire (KCCQ).
The RAND12 is a short, well-validated, generic measure of
health status [10-12]. The patients overall physical and
mental health status was evaluated using the United States
(US) population standardized Physical Component Sum-
mary (PCS) and the Mental Component Summary (MCS)
scores [10,11].
The EQ-5D is a 5-item self-administered utility measure
[13]. In addition to the 5 health state items, the EQ-5DHealth and Quality of Life Outcomes 2006, 4:89 http://www.hqlo.com/content/4/1/89
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also contains a visual analog scale (EQ-VAS). Utility
scores are generated using the time-trade off approach
where the responses to the five items are valued based on
general population valuation scores. Health state valua-
tions are available for both the United Kingdom (UK)
[13] and more recently the US [14,15].
The KCCQ is a 23-item heart failure specific question-
naire. The KCCQ has domains on physical limitations,
heart failure specific symptoms (e.g., swelling, shortness
of breath, fatigue), quality of life, social impact of the dis-
ease, and patients' assessments of their disease knowledge
or self-efficacy [16]. The psychometric properties of the
measure have been previously established [2,16]. In addi-
tion to domain scores, the KCCQ generates two summary
measures, the KCCQ Clinical Summary Score (capturing
patients' physical function and symptoms) and KCCQ
Overall Summary Score (including the physical and social
function, symptoms and quality of life domains). These
summary scores were used for all analyses involving the
KCCQ.
In addition to the HRQL questionnaires, several clinical
assessments were also completed by the residing cardiol-
ogist at baseline. Specifically, the patients baseline New
York Heart Association (NYHA) classification was
assessed and patients completed a six-minute walk (6
MW) test according to a standardized protocol [17]. All
patients returned to the medical center after approxi-
mately 6 weeks for repeat assessment by the cardiologist.
All measures, including HRQL questionnaires (i.e.,
RAND12, EQ-5D, and KCCQ), NYHA classification, and
6 MW tests were re-evaluated.
Criteria for clinical change
There is no universally accepted gold standard for identi-
fication of clinical change in patients with heart failure. As
a result, change in the patients' clinical status was assessed
using several criteria. First, cardiologist's assessment of the
patients' NYHA classification at baseline and at the 6-
week follow-up was used. Subjects were classified as
improving two NYHA classes (e.g., improving from NYHA
class IV to NYHA class II), improving one NYHA class, no
change in NYHA class, and deteriorating one NYHA class
from the baseline to 6-week follow-up. No subjects dete-
riorated by two NYHA classes during the 6-week period.
Second, the resident cardiologist, blinded to the subjects
self-reported HRQL and the 6 MW test results, completed
a previously validated global rating of change assessment
from the baseline to the 6-week follow-up visit [2,18].
This provides a 15-point Likert scale ranging from
extremely worse (-7), no change (zero), to extremely bet-
ter (+7). Subjects were classified into 5 mutually exclusive
change categories: substantially improved (+7, +6, +5),
moderately improved (+4,+3,+2), no change (+1, 0, -1),
moderately deteriorated (-2, -3, -4), and substantially
deteriorated (-5, -6, -7).
Finally, the difference from baseline to 6-weeks in dis-
tanced traveled in the 6 MW test was recorded. This differ-
ence was categorized into 7 mutually exclusive categories
of clinical change according to previous research [2]: sub-
stantially improved (≥ +100 meters); moderately
improved (+50 to +99 meters), small improvement (+25
to +49 meters), no change (+24 to -24 meters), small dete-
rioration (-25 to -99 meters), moderately deteriorated (-
100 to -199 meters), and substantial deterioration (≤ -200
meters).
Analysis
Mean change scores in the HRQL measures were calcu-
lated by subtracting the baseline score from the 6-week
follow-up data. Responsiveness indices, including T-sta-
tistic (mean change divided by standard deviation for
total group), effect size (ES) (mean change divided by the
standard deviation of the baseline score), the Guyatt's
responsiveness statistic (GRS) (mean change divided by
the standard deviation of change in subjects who
remained unchanged), and the standardized response
mean (SRM) (mean change divided by the standard devi-
ation of the change score) [9], were calculated for each of
the HRQL measures (i.e., RAND12–MCS and PCS Scores,
EQ-5D–US, EQ-5D–UK, and EQ–VAS, and the KCCQ–
Overall Summary Score and Clinical Summary Score)
between patients who changed and remained stable from
baseline to 6-weeks [9]. The responsiveness indices were
calculated for each of the HRQL measures according to the
degree of change as identified by the three primary exter-
nal indicators of heart failure status change.
To facilitate comparison, the median rank of each HRQL
measure was determined across each of the four respon-
siveness indices [19]. In order for a HRQL measure to be
a valid measure of clinical change, the measure must be
capable of capturing both improvements and deteriora-
tion in clinical status. As a result, categories for improve-
ment and deterioration were combined to provide an
overall single median rank, depicting the overall relative
responsiveness of the HRQL measure to changes in heart
failure clinical status. Of note, the HRQL scores in subjects
who remained stable (i.e., no change categories) were not
included in the calculation of the overall single median
rank of responsiveness.
Results
A total of 476 subjects were enrolled in the study and pro-
vided baseline and 6-week follow-up [2]. Of these sub-
jects, 298 had complete data and were included. Subjects
included in the analysis did not differ in age, sex, bodyHealth and Quality of Life Outcomes 2006, 4:89 http://www.hqlo.com/content/4/1/89
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mass index, comorbidities, heart failure symptoms, or
baseline health status compared to the total cohort (p >
0.05 for all comparisons). Subjects were mainly elderly,
male, overweight, and had a significant history of other
comorbidities (Table 1). Most subjects were in NYHA
class II and III heart failure indicating moderate to severe
heart failure symptoms. Overall, baseline scores indicate
subjects reported substantial deficits in their HRQL con-
sistent with the clinical indicators of their condition
(Table 2).
Classification according to clinical criteria
Upon follow-up (average 6 ± 2 weeks), 52 (17%) subjects
were classified as improved according to the NYHA class
(Table 3), 60 (20%) subjects improved according to the
global rating of change (Table 4), and 101 (34%) subjects
improved according to the 6 MW test (Table 5). Con-
versely, 40 (13%) subjects were classified as deteriorated
according to the NYHA class, 32 (11%) subjects deterio-
rated according to the global rating of change, and 83
(28%) subjects deteriorated according to the 6 MW test.
Overall, 206 (69%) subjects were classified as not
changed according to both the NYHA class (Table 3) and
the global rating of change (Table 4) and 114 (38%)
according to 6 MW test (Table 5).
HRQL responsiveness to change
Overall, the magnitude of change in the HRQL scores
were larger for subjects who improved compared to sub-
jects who deteriorated over the 6-week period, with the
exception of the 6 MW data, which showed the opposite
trend (Table 5). Importantly, however, fewer subjects
were classified as having deteriorated over the follow-up
period, irrespective of the external criterion used (Tables
3, 4, 5). As expected, relatively small changes in HRQL
scores occurred in subjects who were classified as having
not changed during the follow-up period on the external
clinical criterions.
Similar to the raw HRQL change scores, the magnitude of
the responsiveness indices were influenced by the direc-
tion of clinical change (Tables 6, 7, 8). Overall, the
responsiveness indices were larger for subjects who
improved during the follow-up period compared to indi-
viduals who deteriorated, irrespective of the responsive-
ness index calculated. For example, the T-statistic for the
EQ-5D–US Scoring system for subjects who improved
substantially (i.e., +5, +6, +7) on the global rating of
change criterion was 2.13 compared to only 1.00 for sub-
jects who substantially deteriorated (i.e., -5,-6,-7) (Table
7). Similar trends were observed in the other HRQL meas-
ures.
In general, the relative ranking of the HRQL measure
within each responsiveness index was similar, regardless
of the responsiveness indices used (Tables 6, 7, 8). Irre-
spective of the responsiveness index used, the KCCQ Clin-
ical Summary Score and Overall Summary Score were
consistently ranked as the most responsive measures (Fig-
ures 1, 2, 3). Interestingly, the KCCQ Overall Summary
Score was ranked as the most responsive measure accord-
ing to the global rating of change (Figure 2) and 6 MW
(Figure 3), but not with respect to the NYHA classification
(Figure 1). This is not surprising as the NYHA Classifica-
tion is focused mainly on the 'clinical' aspects of heart fail-
ure (symptoms and function). As a result, this criterion is
more attuned to the KCCQ Clinical Summary Score com-
pared to the KCCQ Overall Summary Score, which also
includes the domains of social function and quality of life.
Although small differences existed, the relative ranking of
the generic HRQL measures across the responsiveness
indices were similar and generally differed by only one
rank position. For example, the EQ-5D–US Scoring sys-
tem for subjects who improved +2 NYHA classes had a rel-
ative ranking of '3' using the T-statistic, ES and GRS and a
rank of '4' using the SRM. Thus, the relative responsive-
ness of a disease-specific versus generic HRQL measure
was not substantively influenced by the choice of respon-
siveness index. Differences did exist, however, in the rela-
tive ranking of generic HRQL measures according to the
external clinical criterion of change used (Tables 6, 7, 8;
Figures 1, 2, 3). The observed differences were relatively
small, however. In general, the EQ-5D scoring systems
and the RAND12 PCS scores were not as responsive as the
RAND12 MCS score or the KCCQ scores.
Discussion
In this study, we found that the disease specific KCCQ
measure was more responsive to underlying clinical
change than either the generic EQ-5D or RAND12 meas-
ures. The greater responsiveness of the KCCQ was consist-
ent across all four responsiveness indices used and across
the three external clinical criteria of change. Importantly,
we also found that the methods and definitions used to
define true underlying change can have a major influence
on the perceived responsiveness of a HRQL measure
[19,20], particularly for the generic HRQL measures. Our
results showed that the generic HRQL measures may be
highly responsive when compared to one clinical anchor
yet less responsive with a different clinical anchor. These
effects were less apparent with the KCCQ. As a result, dif-
ferent methods used to judge whether an important
change has occurred in a patient can lead to different con-
clusions regarding the responsiveness of a HRQL measure.
These are important results, given the broad range of
approaches that may be applied in the assessment of
responsiveness [9].Health and Quality of Life Outcomes 2006, 4:89 http://www.hqlo.com/content/4/1/89
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It is important to understand and interpret how changes
in the HRQL scores over time reflect true  underlying
change in patients with heart failure. Clinicians are inter-
ested in determining if the difference in HRQL scores over
time signifies a trivial, small but clinically important,
moderate, or a large change in HRQL [5,21]. This infor-
mation is critical in guiding clinical decisions with respect
to the patients' management. Furthermore, in the clinical
trial setting, this information is equally important to
Table 1: Baseline Characteristics
Characteristic (n = 298) Number (%) or Mean ± SD
Demographics
Age 60 ± 13





Body mass index 29.0 ± 6.5*
Co-Morbidities
History Hypertension 159 (53)
History of angina 66 (22)
History of myocardial infarction 112 (38)
History of percutaneous coronary intervention 41 (14)
History of coronary artery bypass graph 82 (28)
History of hyperlipidemia 135 (45)
History of diabetes 99 (33)
History of renal failure 15 (5)
History of COPD/Asthma 56 (19)
Heart Failure
Etiology †
- Ischemia 146 (50)
- Hypertensive 25 (8)
- Valvular heart disease 8 (3)
- Other 110 (38)
Ejection fraction 25 ± 8.1
Heart Rate 73 ± 14
Systolic blood pressure 121 ± 24
Diastolic blood pressure 69 ± 13
Receiving ACE inhibitors 242 (81)
Receiving beta-blockers 224 (75)
Receiving spironolactone 106 (36)
*–1 subject missing data; †–9 subjects missing data; COPD -Chronic Obstructive Pulmonary Disease
Table 2: Baseline Health Status and Clinical Measures
Health Status Measure (n = 298) Number (%) or Mean ± SD
RAND12–PCS 35.0 ± 10.7
RAND12–MCS 48.4 ± 11.4
EQ5D–UK Valuation 0.66 ± 0.26
EQ5D–US Valuation 0.74 ± 0.17
EQ–VAS 62.6 ± 20.5*
KCCQ–Clinical Summary Score 65.8 ± 23.3






Six minute walk distance (m) 305 ± 112
*–7 people missing baseline valuesHealth and Quality of Life Outcomes 2006, 4:89 http://www.hqlo.com/content/4/1/89
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determine if there is sufficient evidence to support a new
treatment modality.
The high responsiveness of the KCCQ may have been
expected as specific measures, by design, typically have
very strong content validity for a specific disease or popu-
lation. It is generally accepted that when true change
occurs in the setting of a clinical trial, disease-specific
measures are more responsive to this change as compared
to generic measures of HRQL [22]. They are often per-
ceived to be more clinically relevant and 'sensible' to both
patients and clinicians [23]. Disease specific measures
generally also explore a single domain in greater depth
compared to a corresponding domain in generic measures
[24].
The KCCQ, for example, specifically focuses on the impact
of dyspnea, a prominent complaint for people with heart
failure. In the RAND12, dyspnea could be captured, but
only in much broader terms under the domain of physical
functioning. Thus, disease-specific measures may be more
sensitive and responsive to within-patient change as com-
Table 3: Baseline, 6 week, and mean change scores according to change in health status according to the external criterion: New York 
Heart Association Classification
n Baseline Score ± Standard 
Deviation
6 Week Score ± Standard 
Deviation
Mean Change Score ± Standard 
Deviation
EQ5D–US Scoring
+2 NYHA Classes 2 0.78 ± 0.11 0.82 ± 0.06 0.04 ± 0.05
+1 NYHA Class 50 0.76 ± 0.16 0.77 ± 0.16 0.01 ± 0.13
No change in NYHA Class 206 0.74 ± 0.18 0.77 ± 0.16 0.03 ± 0.13
-1 NYHA Class 40 0.73 ± 0.18 0.74 ± 0.17 0.01 ± 0.12
-2 NYHA Classes 0 ---
EQ5D–UK Scoring
+2 NYHA Classes 2 0.75 ± 0.19 0.79 ± 0.14 0.04 ± 0.05
+1 NYHA Class 50 0.68 ± 0.25 0.70 ± 0.24 0.02 ± 0.19
No change in NYHA Class 206 0.66 ± 0.27 0.71 ± 0.22 0.05 ± 0.20
-1 NYHA Class 40 0.65 ± 0.27 0.65 ± 0.25 0.00 ± 0.19
-2 NYHA Classes 0 ---
EQ–VAS
+2 NYHA Classes 2 71.00 ± 12.73 77.50 ± 10.61 6.50 ± 2.12
+1 NYHA Class 46 59.83 ± 21.05 62.10 ± 21.32 1.09 ± 23.84
No change in NYHA Class 198 63.95 ± 20.05 65.74 ± 20.62 1.45 ± 16.17
-1 NYHA Class 37 58.88 ± 21.88 60.38 ± 22.31 2.68 ± 18.56
-2 NYHA Classes 0 ---
KCCQ OVERALL SUMMARY SCORE
+2 NYHA Classes 2 72.27 ± 1.66 78.65 ± 12.52 6.38 ± 14.18
+1 NYHA Class 50 60.87 ± 24.30 65.65 ± 21.39 4.77 ± 15.60
No change in NYHA Class 206 61.87 ± 24.25 63.84 ± 24.23 1.97 ± 11.49
-1 NYHA Class 40 58.93 ± 23.63 54.56 ± 22.48 -4.37 ± 13.05
-2 NYHA Classes 0 ---
KCCQ CLINCAL SUMMARY SCORE
+2 NYHA Classes 2 73.18 ± 8.47 76.04 ± 10.31 2.86 ± 18.78
+1 NYHA Class 50 65.98 ± 23.24 71.10 ± 18.64 5.11 ± 15.75
No change in NYHA Class 206 65.85 ± 23.63 67.50 ± 23.74 1.65 ± 11.59
-1 NYHA Class 40 64.70 ± 22.37 59.59 ± 22.02 -5.1 ± 11.51
-2 NYHA Classes 0 ---
RAND12 PCS
+2 NYHA Classes 2 40.15 ± 9.86 37.39 ± 6.53 -2.77 ± 3.33
+1 NYHA Class 50 33.69 ± 10.4 35.08 ± 9.87 1.40 ± 9.20
No change in NYHA Class 206 35.69 ± 11.09 36.58 ± 11.02 0.89 ± 6.47
-1 NYHA Class 40 32.71 ± 8.89 33.02 ± 8.28 0.31 ± 6.22
-2 NYHA Classes 0 ---
RAND12 MCS
+2 NYHA Classes 2 45.44 ± 22.36 51.01 ± 17.25 5.57 ± 5.11
+1 NYHA Class 50 50.40 ± 9.98 49.43 ± 10.61 -0.97 ± 10.19
No change in NYHA Class 206 48.03 ± 11.55 48.45 ± 11.24 0.41 ± 8.35
-1 NYHA Class 40 48.22 ± 12.18 46.00 ± 11.80 -2.21 ± 9.89
-2 NYHA Classes 0 ---Health and Quality of Life Outcomes 2006, 4:89 http://www.hqlo.com/content/4/1/89
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pared to generic measures [22]. This change in HRQL is
often easier to identify using disease specific measures
since changes observed on the measure are often more
closely associated with changes in clinical measurements
which are familiar to clinicians [25]. In addition, the
lower responsiveness of the generic measures may also be
due, in part, to the presence of other competing comor-
bidities that can influence generic measures, other than
the severity or changes in the patient's heart failure. As a
result, the stronger responsiveness of the KCCQ may have
been expected.
While our data would suggest that the use of a disease-spe-
cific measure, like the KCCQ, may provide the best oppor-
tunity to capture small but highly relevant clinical changes
in heart failure patients, not all changes in HRQL may be
captured with the use of a disease-specific measure, as
often the overall effects of a new treatment may not be
fully known. For example, we were intrigued by the rela-
tive performance of the physical and mental health sum-
mary scores of the RAND12. Although heart failure is
often perceived largely as a physical disease, the RAND12
PCS Score performed very poorly compared to the other
Table 4: Baseline, 6 week, and mean change scores according to change in health status according to the external criterion: Global 
Rating of Change
n Baseline Score ± Standard 
Deviation
6 Week Score ± Standard 
Deviation
Mean Change Score ± 
Standard Deviation
EQ5D–US Scoring
Substantial Increase (+ 5,6,7) 7 0.74 ± 0.18 0.88 ± 0.12 0.14 ± 0.17
Moderate Increase (+2,+3,+4) 53 0.76 ± 0.15 0.79 ± 0.13 0.02 ± 0.12
No Change (-1,0,+1) 206 0.74 ± 0.18 0.77 ± 0.16 0.03 ± 0.13
Moderate Decrease (-2,-3,-4) 30 0.74 ± 0.15 0.73 ± 0.12 -0.01 ± 0.11
Substantial Decrease (-5,-6,-7) 2 0.46 ± 0.19 0.43 ± 0.24 -0.03 ± 0.05
EQ5D–UK Scoring
Substantial Increase (+ 5,6,7) 7 0.65 ± 0.28 0.86 ± 0.16 0.21 ± 0.26
Moderate Increase (+2,+3,+4) 53 0.70 ± 0.23 0.73 ± 0.18 0.03 ± 0.20
No Change (-1,0,+1) 206 0.66 ± 0.27 0.70 ± 0.24 0.04 ± 0.19
Moderate Decrease (-2,-3,-4) 30 0.66 ± 0.22 0.65 ± 0.18 -0.01 ± 0.19
Substantial Decrease (-5,-6,-7) 2 0.27 ± 0.34 0.22 ± 0.42 -0.05 ± 0.07
ED–VAS
Substantial Increase (+ 5,6,7) 5 54.80 ± 34.28 75.71 ± 25.24 19.2 ± 22.26
Moderate Increase (+2,+3,+4) 51 64.66 ± 20.96 67.25 ± 20.37 2.90 ± 23.39
No Change (-1,0,+1) 196 63.05 ± 20.27 65.16 ± 20.52 1.70 ± 15.92
Moderate Decrease (-2,-3,-4) 29 58.07 ± 18.91 55.00 ± 20.31 -2.66 ± 15.64
Substantial Decrease (-5,-6,-7) 2 55.00 ± 7.07 30.00 ± 14.14 -25.00 ± 21.21
KCCQ OVERALL SUMMARY SCORE
Substantial Increase (+ 5,6,7) 7 51.26 ± 30.57 70.98 ± 27.65 19.72 ± 17.24
Moderate Increase (+2,+3,+4) 53 63.79 ± 20.38 68.47 ± 18.43 4.69 ± 15.84
No Change (-1,0,+1) 206 62.33 ± 24.81 63.86 ± 24.16 1.52 ± 10.82
Moderate Decrease (-2,-3,-4) 30 55.54 ± 21.12 48.82 ± 19.80 -6.72 ± 11.61
Substantial Decrease (-5,-6,-7) 2 21.88 ± 8.84 13.28 ± 6.26 -8.59 ± 2.58
KCCQ CLINCAL SUMMARY SCORE
Substantial Increase (+ 5,6,7) 7 56.55 ± 31.08 74.40 ± 21.88 17.86 ± 16.53
Moderate Increase (+2,+3,+4) 53 69.24 ± 20.42 72.54 ± 16.59 3.30 ± 16.58
No Change (-1,0,+1) 206 66.38 ± 23.78 67.74 ± 23.71 1.36 ± 10.83
Moderate Decrease (-2,-3,-4) 30 60.46 ± 19.73 54.94 ± 18.96 -5.52 ± 11.55
Substantial Decrease (-5,-6,-7) 2 22.92 ± 14.73 14.58 ± 7.37 -8.33 ± 7.37
RAND12 PCS
Substantial Increase (+ 5,6,7) 7 29.29 ± 12.53 41.00 ± 13.79 11.71 ± 10.41
Moderate Increase (+2,+3,+4) 53 35.66 ± 10.99 36.66 ± 9.64 1.00 ± 7.82
No Change (-1,0,+1) 206 35.51 ± 10.81 36.34 ± 10.69 0.83 ± 6.43
Moderate Decrease (-2,-3,-4) 30 32.66 ± 8.00 31.00 ± 8.06 -1.66 ± 5.72
Substantial Decrease (-5,-6,-7) 2 17.76 ± 1.36 19.21 ± 2.99 1.45 ± 4.36
RAND12 MCS
Substantial Increase (+ 5,6,7) 7 54.23 ± 13.01 49.04 ± 12.92 -5.19 ± 10.47
Moderate Increase (+2,+3,+4) 53 48.41 ± 11.40 51.61 ± 10.00 3.20 ± 10.61
No Change (-1,0,+1) 206 48.73 ± 11.49 48.26 ± 11.27 -0.47± 8.11
Moderate Decrease (-2,-3,-4) 30 45.40 ± 10.54 42.98 ± 11.17 -2.41 ± 9.46
Substantial Decrease (-5,-6,-7) 2 44.56 ± 10.15 42.43 ± 7.13 -2.14 ± 3.03Health and Quality of Life Outcomes 2006, 4:89 http://www.hqlo.com/content/4/1/89
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Table 5: Baseline, 6 week, and mean change scores according to change in health status according to the external criterion: Six-Minute 
Walk Test (meters)
n Baseline Score ± Standard 
Deviation
6 Week Score ± Standard 
Deviation
Mean Change Score ± Standard 
Deviation
EQ5D–US Scoring
<= -200 7 0.69 ± 0.11 0.68 ± 0.14 -0.02 ± 0.09
-199 to -100 16 0.66 ± 0.24 0.68 ± 0.20 0.02 ± 0.12
-99 to -25 60 0.72 ± 0.17 0.75 ± 0.16 0.04 ± 0.15
-24 to +24 114 0.77 ± 0.17 0.77 ± 0.15 0.00 ± 0.11
25 to 49 33 0.77 ± 0.16 0.80 ± 0.13 0.04 ± 0.13
50 to 99 40 0.72 ± 0.18 0.78 ± 0.16 0.05 ± 0.14
>= 100 28 0.76 ± 0.16 0.80 ± 0.16 0.04 ± 0.11
EQ5D–UK Scoring
<= -200 7 0.59 ± 0.18 0.59 ± 0.22 0.00 ± 0.12
-199 to -100 16 0.53 ± 0.35 0.56 ± 0.32 0.03 ± 0.20
-99 to -25 60 0.62 ± 0.26 0.68 ± 0.24 0.06 ± 0.23
-24 to +24 114 0.70 ± 0.25 0.71 ± 0.22 0.01 ± 0.17
25 to 49 33 0.70 ± 0.23 0.75 ± 0.19 0.05 ± 0.17
50 to 99 40 0.63 ± 0.28 0.71 ± 0.23 0.08 ± 0.23
>= 100 28 0.69 ± 0.24 0.74 ± 0.24 0.05 ± 0.16
EQ–VAS
= -200 7 60.43 ± 15.04 50.71 ± 21.30 -9.71 ± 20.95
-199 to -100 15 58.38 ± 27.40 49.00 ± 31.12 -8.60 ± 23.21
-99 to -25 56 60.53 ± 19.33 63.92 ± 21.71 2.32 ± 18.94
-24 to +24 109 64.94 ± 19.06 66.13 ± 20.19 1.24 ± 17.59
25 to 49 31 66.41 ± 18.46 68.84 ± 17.37 2.52 ± 13.28
50 to 99 38 60.89 ± 23.83 65.60 ± 17.66 3.82 ± 17.46
>= 100 27 58.41 ± 22.41 64.86 ± 20.93 5.89 ± 15.84
KCCQ OVERALL SUMMARY SCORE
<= -200 7 45.44 ± 22.81 45.44 ± 22.81 -7.75 ± 13.19
-199 to -100 16 53.42 ± 24.82 53.42 ± 24.82 -5.00 ± 6.20
-99 to -25 60 61.54 ± 24.20 61.54 ± 24.20 0.08 ± 13.99
-24 to +24 114 62.82 ± 23.30 62.82 ± 23.30 1.47 ± 10.94
25 to 49 33 67.41 ± 23.69 67.41 ± 23.69 0.17 ± 12.09
50 to 99 40 59.35 ± 26.26 59.35 ± 26.26 3.74 ± 16.69
>= 100 28 59.48 ± 21.64 59.48 ± 22.89 10.3 ± 14.08
KCCQ CLINCAL SUMMARY SCORE
<= -200 7 45.64 ± 26.24 37.28 ± 25.84 -8.36 ± 11.76
-199 to -100 16 58.93 ± 22.54 55.89 ± 25.92 -3.03 ± 9.85
-99 to -25 60 65.01 ± 23.73 65.54 ± 23.94 0.53 ± 13.30
-24 to +24 114 67.07 ± 22.07 67.72 ± 21.66 0.65 ± 11.68
25 to 49 33 72.41 ± 22.48 72.39 ± 22.91 -0.02 ± 10.96
50 to 99 40 64.45 ± 25.65 68.61 ± 20.59 4.16 ± 13.72
>= 100 28 65.10 ± 22.37 73.41 ± 19.31 8.31 ± 14.24
RAND12 PCS
<= -200 7 25.49 ± 9.07 25.74 ± 6.88 0.25 ± 8.15
-199 to -100 16 32.28 ± 12.07 34.7 ± 12.05 2.42 ± 5.58
-99 to -25 60 35.10 ± 10.31 25.55 ± 10.45 0.45 ± 6.91
-24 to +24 114 34.79 ± 10.05 35.99 ± 10.24 1.20 ± 6.38
25 to 49 33 38.28 ± 11.51 37.90 ± 10.4 -0.38 ± 5.94
50 to 99 40 36.03 ± 10.94 35.80 ± 10.91 -0.23 ± 7.29
>= 100 28 34.09 ± 11.65 36.81 ± 10.64 2.72 ± 9.72
RAND12 MCS
<= -200 7 47.28 ± 5.87 43.74 ± 9.05 -3.53 ± 6.21
-199 to -100 16 46.65 ± 13.15 38.56 ± 11.92 -8.09 ± 14.05
-99 to -25 60 47.66 ± 11.96 46.92 ± 11.38 -0.74 ± 7.87
-24 to +24 114 49.47 ± 11.14 49.67 ± 10.91 0.19 ± 8.55
25 to 49 33 47.74 ± 11.38 48.82 ± 10.86 1.08 ± 7.33
50 to 99 40 46.85 ± 11.22 48.38 ± 10.52 1.54 ± 8.71
>= 100 28 50.27 ± 12.16 51.37 ± 11.06 1.40 ± 9.43Health and Quality of Life Outcomes 2006, 4:89 http://www.hqlo.com/content/4/1/89
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HRQL measures. The reason for the lower responsiveness
of the RAND12 PCS is not known but may be related to
the underlying health status of the study population.
RAND12 PCS scores were, on average, 1.5 standard devia-
tions below the standardized US population mean at
baseline indicating that the subjects had significant phys-
ical deficits (Table 2). As a result, it is possible that sub-
jects were too limited, physically, to change over the 6-
week follow-up period significantly. Alternatively, since
patients recruited in the study were from the outpatient
setting, patients would be expected to have 'relatively' sta-
ble heart failure symptoms. As a result, significant physi-
cal changes may not necessarily be expected over the 6-
week period. Interestingly, however, the RAND12 MCS
was relatively more responsive to changes in heart failure
status. The impact of mental health and its monitoring in
patients with heart failure warrants further investigation
[26].
Also of note was that the relative responsiveness of the
HRQL measures depended on the direction of clinical
change. Overall, the HRQL measures were more respon-
sive to improved clinical status as compared to deteriorat-
ing clinical status. This may be related to the fact that heart
failure patients in this study were quite severely affected
by their disease and had substantial deficits in their
HRQL. As a result, HRQL measures may be susceptible to
'floor effects' in this population, which may limit their
ability to capture deterioration in clinical status. The
observation that no patient deteriorated by 2 NYHA
classes further supports this hypothesis. Thus, not only
can the responsiveness indices and external criterion
standards influence instrument responsiveness, but also it
is important to consider the population studied.
Irrespective of the scope of the HRQL measure or the
direction of clinical change, the responsiveness of a partic-
ular measure may also be influenced by the responsive-
ness index used. Although the responsiveness indices used
in this study provided similar rankings, differences did
exist among the responsiveness indices when the generic
HRQL measures were concerned. In this study, four com-
monly utilized responsiveness indices were used [9,27].
Terwee et al. have shown that there are over 30 different
Table 6: Responsiveness statistics and relative ranking of selected HRQL measures according to change on the external criterion: New 
York Heart Association





EQ5D–US Scoring 2 1.00 (3) 0.36 (3) 0.31 (4) 0.80 (3) 3.00  
EQ5D–UK Scoring 2 1.00 (3) 0.21 (6) 0.20 (6) 0.80 (3) 4.50
EQ–VAS 2 4.33 (1) 0.51 (2) 0.40 (3) 3.07 (1) 1.50
KCCQ Overall Summary Score 2 0.64 (5) 3.84 (1) 0.56 (2) 0.45 (5) 3.50
KCCQ Clinical Summary Score 2 0.22(6) 0.34 (4) 0.25 (5) 0.15 (6) 5.50
RAND12 PCS 2 -1.17 (7) -0.28 (7) -0.43 (7) -0.83 (7) 7.00  
RAND12 MCS 2 1.54 (2) 0.25 (5) 0.67 (1) 1.09 (2) 2.00
Improved +1 NYHA Classes
EQ5D–US Scoring 50 0.80 (4) 0.06 (5) 0.08 (5) 0.08 (5) 5.00
EQ5D–UK Scoring 50 0.73 (5) 0.08 (4) 0.10 (4) 0.11 (4) 4.00
EQ–VAS 46 0.31 (6) 0.05 (6) 0.07 (6) 0.05 (6) 6.00
KCCQ Overall Summary Score 50 2.16 (2) 0.20 (2) 0.42 (2) 0.31 (2) 2.00
KCCQ Clinical Summary Score 50 2.30 (1) 0.22 (1) 0.44 (1) 0.32 (1) 1.00
RAND12 PCS 50 1.07 (3) 0.13 (3) 0.22 (3) 0.15 (3) 3.00
RAND12 MCS -0.67 (7) -0.10 (7) -0.12 (7) -0.10 (7) 7.00
No Change in NHYA Class
EQ5D–US Scoring 206 3.43 0.17 0.23 0.23 -
EQ5D–UK Scoring 206 3.45 0.19 0.25 0.25 -
EQ–VAS 198 1.27 0.07 0.09 0.09 -
KCCQ Overall Summary Score 206 2.46 0.08 0.17 0.17 -
KCCQ Clinical Summary Score 206 2.05 0.07 0.14 0.14 -
RAND12 PCS 206 1.97 0.08 0.14 0.14 -
RAND12 MCS 206 0.71 0.04 0.05 0.05 -
Deteriorated -1 NYHA 
Classes
EQ5D–US Scoring 40 0.26 (5) 0.06 (6) 0.08 (6) 0.08 (6) 6.00
EQ5D–UK Scoring 40 0.12 (4) 0.00 (4) 0.00 (4) 0.00 (4) 4.00
EQ–VAS 37 0.88 (7) 0.12 (7) 0.17 (7) 0.14 (7) 7.00
KCCQ Overall Summary Score 40 -2.12 (2) -0.18 (2) -0.38 (2) -0.33 (2) 2.00
KCCQ Clinical Summary Score 40 -2.80 (1) -0.23 (1) -0.44 (1) -0.44 (1) 1.00
RAND12 PCS 40 0.31 (6) 0.03 (5) 0.05 (5) 0.05 (5) 5.00
RAND12 MCS 40 -1.41 (3) -0.18 (3) -0.26 (3) -0.22 (3) 3.00
Deteriorated -2 NYHA 
Classes
0 Not Calculated Due to No subjectsHealth and Quality of Life Outcomes 2006, 4:89 http://www.hqlo.com/content/4/1/89
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responsiveness calculations which have been described in
the literature to identify change in a patient's HRQL [9].
Although most indices use the mean change in HRQL
over time, there are significant differences in how the
standard deviations or variability in the data is used in the
calculation. For example, the GRS was calculated using
the standard deviation of the change scores among sub-
jects who are clinically stable, whereas the SRM uses the
standard deviation of the change scores. It is therefore
possible that significant differences could exist in the var-
iability in the selected subgroups, resulting in differences
in the perceived responsiveness of the HRQL measure
depending upon the responsiveness index chosen.
Our results and interpretation should be considered in
light of several potential limitations. First, as discussed,
the ability to identify patients who truly changed during
the follow-up period was subjective, as no 'gold standard'
exists for patients with heart failure. We did apply, how-
ever, the NYHA classification system, physician global rat-
ing of change assessment, and 6 MW tests, which are well
validated and common methods to identify change in
clinical status in patients with heart failure [2,17,18]. Fur-
thermore, the same cardiologist evaluated subjects at both
the baseline and the 6-week follow-up improving internal
consistency of these change ratings and may provide the
most appropriate method for validating the HRQL meas-
ures ability to identify true clinical change in this popula-
tion [2]. Second, the categorical cut points used in the 6
Table 7: Responsiveness statistics and relative ranking of selected HRQL measures according to change on the external criterion: 
Global Rating of Change
Global Change Score – Substantial 
Increase +5,+6,+7







EQ5D–US Scoring 7 2.13 (4) 0.78 (2) 1.08 (6) 0.82 (5) 4.50
EQ5D–UK Scoring 7 2.10 (5) 0.75 (3) 1.11 (5) 0.81 (6) 5.00
EQ–VAS 5 1.93 (6) 0.56 (6) 1.21 (4) 0.86 (4) 5.00
KCCQ Overall Summary Score 7 3.03 (1) 0.65 (4) 1.82 (1) 1.14 (1) 1.00
KCCQ Clinical Summary Score 7 2.86 (3) 0.57 (5) 1.65 (3) 1.08 (3) 3.00
RAND12 PCS 7 2.98 (2) 0.93 (1) 1.82 (2) 1.12 (2) 2.00
RAND12 MCS 7 -1.31 (7) -0.40 (7) -0.64 (7) -0.50 (7) 7.00
Global Change Score – Moderate 
Increase +2,+3,+4
EQ5D–US Scoring 53 1.37 (4) 0.13 (5) 0.15 (7) 0.17 (4) 4.50
EQ5D–UK Scoring 53 1.23 (5) 0.13 (6) 0.16 (5) 0.15 (5) 5.00
EQ–VAS 51 0.89 (7) 0.14 (4) 0.18 (4) 0.12 (7) 5.50
KCCQ Overall Summary Score 53 2.15 (2) 0.23 (2) 0.43 (1) 0.30 (2) 2.00
KCCQ Clinical Summary Score 53 1.45 (3) 0.16 (3) 0.30 (3) 0.20 (3) 3.00
RAND12 PCS 53 0.93 (6) 0.09 (7) 0.16 (6) 0.13 (6) 6.00
RAND12 MCS 53 2.20 (1) 0.28 (1) 0.39 (2) 0.30 (1) 1.00
Global Change Score – No Change -
1,0,+1
EQ5D–US Scoring 206 2.94 0.17 0.23 0.23 -
EQ5D–UK Scoring 206 3.00 0.15 0.21 0.21 -
EQ–VAS 196 1.49 0.08 0.11 0.11 -
KCCQ Overall Summary Score 206 2.02 0.06 0.14 0.14 -
KCCQ Clinical Summary Score 206 1.80 0.06 0.13 0.13 -
RAND12 PCS 206 1.85 0.08 0.13 0.13 -
RAND12 MCS 206 -0.83 -0.04 -0.06 -0.06 -
Global Change Score – Moderate 
Deterioration -2,-3,-4
EQ5D–US Scoring 30 -0.31 (6) -0.07 (6) -0.08 (6) -0.09 (6) 6.00
EQ5D–UK Scoring 30 -0.29 (7) -0.05 (7) -0.05 (7) -0.05 (7) 7.00
EQ–VAS 29 -0.91 (5) -0.14 (5) -0.17 (5) -0.17 (5) 5.00
KCCQ Overall Summary Score 30 -3.17 (1) -0.32 (1) -0.62 (1) -0.58 (1) 1.00
KCCQ Clinical Summary Score 30 -2.62 (2) -0.28 (2) -0.51 (2) -0.48 (2) 2.00
RAND12 PCS 30 -1.59 (3) -0.21 (4) -0.26 (4) -0.29(3) 3.50
RAND12 MCS 30 -1.40 (4) -0.23 (3) -0.30 (3) -0.25 (4) 3.50
Global Change Score – Substantial 
Deterioration -5,-6,-7
EQ5D–US Scoring 2 -1.00 (4) -0.16 (5) -0.23 (6) -0.60 (6) 5.50
EQ5D–UK Scoring 2 -1.00 (4) -0.15 (6) -0.26 (5) -0.71 (4) 4.50
EQ–VAS 2 -1.67 (2) -3.54 (1) -1.57 (1) -1.18 (2) 1.50
KCCQ Overall Summary Score 2 -4.71 (1) -0.97 (2) -0.79 (2) -3.33 (1) 1.50
KCCQ Clinical Summary Score 2 -1.60 (3) -0.57 (3) -0.77 (3) -1.13 (3) 3.00
RAND12 PCS 2 0.47 (7) 1.07 (7) 0.23 (7) 0.33 (7) 7.00
RAND12 MCS 2 -1.00 (4) -0.21 (4) -0.26 (4) -0.71 (5) 4.00Health and Quality of Life Outcomes 2006, 4:89 http://www.hqlo.com/content/4/1/89
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MW data to indicate the magnitude of clinical change may
have affected the responsiveness results. We did reanalyze
the data using different categorical cut points, but
obtained the same relative ranking of the HRQL measures.
As a result, it is unlikely that changes in the cut points for
the clinical change categories for the 6 MW data would
significantly alter our results. Third, fifteen subjects were
missing either baseline or 6-week EQ-VAS scores. It is pos-
sible that restricting the sample to subjects who had com-
plete responses on all the HRQL measures may have
changed the relative ranking of the HRQL measures. We
feel this is unlikely, however, as the majority of subjects
Table 8: Responsiveness statistics and relative ranking of selected HRQL measures according to change on the external criterion: Six-
Minute Walk Test







EQ5D–US Scoring 7 -0.45 (5) -0.18 (5) -0.18 (5) -0.22 (5) 5.00
EQ5D–UK Scoring 7 -0.06 (6) 0.00 (6) 0.00 (6) 0.00 (6) 6.00
EQ–VAS 7 -1.23 (4) -0.65 (1) -0.55 (3) -0.46 (4) 3.50
KCCQ Overall Summary Score 7 -1.56 (2) -0.34 (3) -0.71 (2) -0.59 (2) 2.00
KCCQ Clinical Summary Score 7 -1.88 (1) -0.32 (4) -0.72 (1) -0.71 (1) 1.00
RAND12 PCS Score 7 0.08 (7) 0.03 (7) 0.04 (7) 0.03 (7) 7.00
RAND12 MCS Score 7 -1.51 (3) -0.60 (2) -0.41 (4) -0.57 (3) 3.00
6 Minute Walk – Deteriorated -199 to -100
EQ5D–US Scoring 16 0.59 (5) 0.08 (5) 0.18 (6) 0.17 (6) 5.50
EQ5D–UK Scoring 16 0.59 (5) 0.09 (6) 0.18 (5) 0.15 (5) 5.00
EQ–VAS 15 -1.44 (3) -0.31 (2) -0.49 (2) -0.37 (3) 2.50
KCCQ Overall Summary Score 16 -3.23 (1) -0.20 (3) -0.46 (3) -0.81 (1) 2.00
KCCQ Clinical Summary Score 16 -1.23 (4) -0.13 (4) -0.26 (4) -0.31 (4) 4.00
RAND12 PCS 16 1.74 (7) 0.20 (7) 0.38 (7) 0.43 (7) 7.00
RAND12 MCS 16 -2.30 (2) -0.62 (1) -0.95 (1) -0.58 (2) 1.50
6 Minute Walk – Deteriorated -99 to -25
EQ5D–US Scoring 60 1.83 (6) 0.24 (7) 0.36 (7) 0.27 (7) 7.00
EQ5D–UK Scoring 60 1.83 (6) 0.23 (6) 0.35 (6) 0.26 (6) 6.00
EQ–VAS 58 0.92 (5) 0.12 (5) 0.13 (5) 0.12 (5) 5.00
KCCQ Overall Summary Score 60 0.04 (2) 0.00 (2) 0.01 (2) 0.01 (2) 2.00
KCCQ Clinical Summary Score 60 0.31 (3) 0.02 (3) 0.05 (3) 0.04 (3) 3.00
RAND12 PCS 60 0.51 (4) 0.04 (4) 0.07 (4) 0.07 (4) 4.00
RAND12 MCS 60 -0.73 (1) -0.06 (1) -0.09 (1) -0.09 (1) 1.00
6 Minute Walk – No Change -24 to 24
EQ5D–US Scoring 114 0.58 0.00 0.00 0.00 -
EQ5D–UK Scoring 114 0.58 0.04 0.06 0.06 -
EQ–VAS 109 0.74 0.07 0.07 0.07 -
KCCQ Overall Summary Score 114 1.44 0.06 0.13 0.13 -
KCCQ Clinical Summary Score 114 0.59 0.03 0.06 0.06 -
RAND12 PCS 114 2.01 0.12 0.19 0.19 -
RAND12 MCS 114 0.24 0.02 0.02 0.02 -
6 Minute Walk – Improved +25 to +49
EQ5D–US Scoring 33 1.66 (1) 0.25 (1) 0.36 (1) 0.31 (1) 1.00
EQ5D–UK Scoring 33 1.66 (1) 0.22 (2) 0.29 (2) 0.29 (2) 2.00
EQ–VAS 31 1.06 (3) 0.14 (3) 0.14 (3) 0.19 (3) 3.00
KCCQ Overall Summary Score 33 0.08 (5) 0.01 (5) 0.02 (5) 0.01 (5) 5.00
KCCQ Clinical Summary Score 33 -0.01 (6) 0.00 (6) 0.00 (6) 0.00 (6) 6.00
RAND12 PCS 33 -0.04 (7) -0.03 (7) -0.06 (7) -0.06 (7) 7.00
RAND12 MCS 33 0.85 (4) 0.09 (4) 0.13 (4) 0.15 (4) 4.00
6 Minute Walk – Improved +50 to +99
EQ5D–US Scoring 40 2.10 (1) 0.28 (2) 0.45 (2) 0.36 (1) 1.50
EQ5D–UK Scoring 40 2.10 (1) 0.29 (1) 0.47 (1) 0.35 (2) 1.00
EQ–VAS 38 1.35 (5) 0.16 (4) 0.22 (5) 0.22 (5) 5.00
KCCQ Overall Summary Score 40 1.73 (4) 0.14 (5) 0.34 (4) 0.22 (4) 4.00
KCCQ Clinical Summary Score 40 1.92 (3) 0.16 (3) 0.36 (3) 0.30 (3) 3.00
RAND12 PCS 40 -0.20 (7) -0.02 (7) -0.04 (7) -0.03 (7) 7.00
RAND12 MCS 40 1.12 (6) 0.14 (6) 0.18 (6) 0.18 (6) 6.00
6 Minute Walk – Improved >= +100
EQ5D–US Scoring 28 1.68 (4) 0.25 (4) 0.36 (4) 0.36 (4) 4.00
EQ5D–UK Scoring 28 1.68 (4) 0.21 (6) 0.29 (6) 0.31 (5) 5.50
EQ–VAS 27 1.93 (3) 0.26 (3) 0.33 (5) 0.37 (3) 3.00
KCCQ Overall Summary Score 28 3.87 (1) 0.48 (1) 0.94 (1) 0.73 (1) 1.00
KCCQ Clinical Summary Score 28 3.09 (2) 0.37 (2) 0.71 (2) 0.58 (2) 2.00
RAND12 PCS 28 1.48 (6) 0.23 (5) 0.43 (3) 0.28 (6) 5.50
RAND12 MCS 28 0.79 (7) 0.12 (7) 0.16 (7) 0.15 (7) 7.00Health and Quality of Life Outcomes 2006, 4:89 http://www.hqlo.com/content/4/1/89
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missing EQ-VAS scores were classified as not changing
over the 6-weeks according to the external criterions.
Thus, the effect of the missing data on the responsiveness
rankings would be minimal. Fourth, we chose to evaluate
four of the more commonly used responsiveness indices
in this study. Numerous other responsiveness indices
have been reported in the literature. While it may be pos-
sible that different results would have been observed if
other responsiveness indices were used, we think that is
unlikely. Finally, the duration of follow-up was relatively
short and may have affected the estimated responsiveness
of the HRQL measures. Each HRQL measure uses a differ-
ent period ranging from 'today' (EQ-5D) to 'within the
past 4 weeks' (RAND12) to assess the patients' health sta-
tus. The 6-week follow-up period was initially chosen to
improve the recall accuracy of the cardiologist evaluating
the patient, yet long enough to allow meaningful clinical
change to occur [2].
With these limitations in mind, we believe this study
highlights the importance of considering the measure-
ment properties and instrument content in selecting
HRQL measures for clinical trials. It is important to have
a measure capable of detecting small but highly relevant
and important changes in HRQL, especially when the
HRQL outcome of interest represents the primary out-
come or main secondary outcome of the trial. Further-
more, in the design of a clinical trial, researchers must be
confident that the HRQL measure is responsive to the
minimal importance difference that was hypothesized
during the study design. The sample size required and
power of the study will be directly related to the minimal
importance difference that the researchers wish to detect.
However, while disease specific measure may be consid-
ered as the first choice for a primary HRQL outcome, a
combination with a generic HRQL measure may still be
desirable to fully assess HRQL outcomes in clinical trial
settings. Further, if the therapy under consideration will
be evaluated under a cost-effectiveness framework, it
would be desirable to include a measure compatible with
that framework, such as a utility-based measure [28].
Overall Relative Rank for Selected HRQL Measures According to External Clinical Criterion: New York Heart Association Figure 1
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Overall Relative Rank for Selected HRQL Measures According to External Clinical Criterion: Six-Minute Walk Test Figure 3
































Overall Relative Rank for Selected HRQL Measures According to External Clinical Criterion: Global Rating of Change Figure 2
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Conclusion
We found the disease specific measure, the KCCQ, was the
most responsive HRQL measure assessing change over a
6-week period, although generic measures provide infor-
mation for which the KCCQ is not suitable. We noted that
the responsiveness of generic HRQL measure may be
affected by the responsiveness index used, as well as the
selection of the external criterion to identify patients who
have clinically change or remained stable.
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